Algernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
May 27, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an...
Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug DMT Clinical Research Program for Stroke
May 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) announces it has received...
Insights on the Intracranial Aneurysm Global Market to 2025 - Competitive Analysis and the Impact of COVID-19
April 21, 2021 06:33 ET
|
Research and Markets
Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Intracranial Aneurysm Market (2020-2025) by Type, Condition, Treatment Type, End-User, Geography, Competitive Analysis and the Impact of...
NovaSignal Launches Platform To Transform Cerebral Blood Flow Measurement
April 14, 2021 09:06 ET
|
NovaSignal Corporation
LOS ANGELES, April 14, 2021 (GLOBE NEWSWIRE) -- NovaSignal Corp., a medical technology and data company specializing in assessing cerebral blood flow, today launched the NovaGuide™ 2 Platform that...
Algernon Pharmaceuticals Announces Appointment of Global Expert Dr. Steven L. Wolf for DMT Stroke Program
April 06, 2021 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, April 06, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...
Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
March 29, 2021 07:02 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia., March 29, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke
March 17, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, March 17, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage...
Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference
February 25, 2021 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Awards DMT Manufacturing Contract to Dalton Pharma for Stroke Program
February 19, 2021 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals Signs Agreement with Charles River Laboratories for DMT Preclinical Studies
February 08, 2021 08:05 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical...